Skip Navigation

Primary Location:

Barnes-Jewish Hospital

Siteman Cancer Center - Division of BMT
660 S Euclid Avenue
Campus Box 8007
St. Louis, MO 63110
(314) 454-8304
(800) 635-2371
http://www.siteman.wustl.edu

Secondary Location:

St. Louis Children's Hospital

Division of Stem Cell Transplantation
1 Children's Place
St. Louis, MO 63110 USA
(314) 454-6018

http://www.stlouischildrens.org/content/

Number of Transplants Performed

This center has been performing allogeneic transplants since 1982 and has been an NMDP transplant center since April 1991.

Transplants Reported (From Jan. 2011 to Dec. 2012 as reported by the centers)       Unrelated or Related Donor Auto-
logous

(PBSC or marrow)
Total (by transplant type)
Marrow PBSC Cord
Blood
Unrelated Donor
- Adult
17 182 4 --- 203
Unrelated Donor
- Pediatric
16 4 1 --- 21
Related Donor
- Adult
2 124 0 --- 126
Related Donor
- Pediatric
12 3 0 --- 15
Autologous
- Adult
--- --- --- 473 473
Autologous
- Pediatric
--- --- --- 16 16
Total
(by cell source)
47 313 5 489 854

To find centers that perform cord blood transplants, use the Search Tool on this site.


Patient Survival Information for this Center

Barnes-Jewish Hospital at Washington University School of Medicine - Adult


This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

  1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2009, 2010 and 2011, and
  2. Who had their transplant at a U.S. transplant center, and
  3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 437 patients.

The actual 1-year survival of these patients is 52.4%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 51.9% and 60.5%.

For help with understanding these statistics, please see Understanding Transplant Outcomes (PDF).

St. Louis Children's Hospital - Pediatrics


This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

  1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2009, 2010 and 2011, and
  2. Who had their transplant at a U.S. transplant center, and
  3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 37 patients.

The actual 1-year survival of these patients is 73.0%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 68.5% and 92.9%.

For help with understanding these statistics, please see Understanding Transplant Outcomes (PDF).


Transplant Results by Patient's Age, Disease Type and Stage

Barnes-Jewish Hospital at Washington Univ. School of Medicine - Adult - Related

Survival by Patient's Age, Disease Type and Stage after Related Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using related donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission -- -- -- -- 4/5 2/4 0/1 6/10
Acute lymphoblastic leukemia in second complete remission -- -- 1/1 -- 1/1 -- -- 2/2
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure -- -- -- 1/3 -- -- -- 1/3
Acute myelogenous leukemia in first complete remission -- -- 1/3 1/2 5/5 8/12 7/13 22/35
Acute myelogenous leukemia in second complete remission -- -- 1/2 -- 2/3 3/5 2/2 8/12
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure -- -- 0/1 2/4 2/8 4/11 0/3 8/27
Chronic lymphocytic leukemia and other chronic leukemia -- -- -- -- 1/1 3/5 1/1 5/7
Chronic myelogenous leukemia in first chronic phase -- -- -- -- -- 1/2 -- 1/2
Chronic myelogenous leukemia in accelerated phase or second chronic phase -- -- -- -- 0/1 -- -- 0/1
Hodgkin lymphoma -- -- -- 2/3 -- -- -- 2/3
Multiple myeloma / Plasma cell disorder -- -- -- -- 1/1 1/3 2/2 4/6
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast -- -- -- -- 1/2 -- 0/2 1/4
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- -- -- -- 2/2 3/9 1/3 6/14
Myelodysplastic disorders - Other MDS -- -- -- -- -- 1/2 0/2 1/4
Myeloproliferative syndromes -- -- -- -- -- 2/2 -- 2/2
Non-Hodgkin lymphoma -- -- 2/2 1/5 5/7 4/7 3/5 15/26
Other acute leukemia -- -- -- -- 1/1 0/1 0/1 1/3
Severe aplastic anemia -- -- 1/1 -- -- -- 1/1 2/2
Total -- -- 6/10 7/17 25/37 32/63 17/36 87/163

Barnes-Jewish Hospital at Washington Univ. School of Medicine - Adult - Unrelated

Survival by Patient's Age, Disease Type and Stage after Unrelated Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using unrelated donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission -- -- 1/1 -- 0/1 0/3 3/4 4/9
Acute lymphoblastic leukemia in second complete remission -- -- 1/2 -- -- -- 0/1 1/3
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure -- -- 1/3 1/2 1/2 -- 1/2 4/9
Acute myelogenous leukemia in first complete remission -- 1/2 5/8 4/7 6/11 7/11 11/15 34/54
Acute myelogenous leukemia in second complete remission -- -- 1/2 2/2 3/4 6/7 3/8 15/23
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure -- -- 2/2 1/2 2/6 7/16 7/20 19/46
Chronic lymphocytic leukemia and other chronic leukemia -- -- -- -- 1/3 1/4 4/5 6/12
Chronic myelogenous leukemia in first chronic phase -- -- 1/1 1/1 -- 1/3 -- 3/5
Chronic myelogenous leukemia in accelerated phase or second chronic phase -- -- -- 1/1 2/3 0/1 0/1 3/6
Hodgkin lymphoma -- 2/3 1/3 1/2 1/2 -- -- 5/10
Multiple myeloma / Plasma cell disorder -- -- 1/1 -- -- 0/2 -- 1/3
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast -- -- -- -- 0/2 1/2 0/2 1/6
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- -- -- 2/2 0/1 2/4 6/12 10/19
Myelodysplastic disorders - Other MDS -- -- -- 0/1 1/3 -- -- 1/4
Myeloproliferative syndromes -- -- -- -- -- 0/1 0/1 0/2
Non-Hodgkin lymphoma -- -- 1/3 3/6 6/9 7/15 4/13 21/46
Other acute leukemia -- -- 1/1 -- -- 1/1 1/2 3/4
Severe aplastic anemia -- -- 1/1 1/2 0/1 1/1 -- 3/5
Total -- 3/5 17/28 17/28 23/48 34/71 40/86 134/266

Barnes-Jewish Hospital at Washington Univ. School of Medicine - Ped - Related

Survival by Patient's Age, Disease Type and Stage after Related Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using related donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission 1/1 1/2 -- -- -- -- -- 2/3
Acute lymphoblastic leukemia in second complete remission 1/1 -- -- -- -- -- -- 1/1
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure -- 0/1 -- -- -- -- -- 0/1
Acute myelogenous leukemia in first complete remission 1/1 1/1 -- -- -- -- -- 2/2
Disorders of the immune system 1/2 1/1 -- -- -- -- -- 2/3
Inherited abnormalities of erythrocyte differentiation or function -- 1/1 -- -- -- -- -- 1/1
Non-Hodgkin lymphoma -- 0/1 -- -- -- -- -- 0/1
Severe aplastic anemia 1/1 4/4 -- -- -- -- -- 5/5
Total 5/6 8/11 -- -- -- -- -- 13/17

Barnes-Jewish Hospital at Washington Univ. School of Medicine - Ped - Unrelated

Survival by Patient's Age, Disease Type and Stage after Unrelated Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using unrelated donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission 1/1 1/1 -- -- -- -- -- 2/2
Acute lymphoblastic leukemia in second complete remission 2/2 -- -- -- -- -- -- 2/2
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure -- 1/1 -- -- -- -- -- 1/1
Acute myelogenous leukemia in first complete remission -- 0/1 -- -- -- -- -- 0/1
Acute myelogenous leukemia in second complete remission -- 1/1 -- -- -- -- -- 1/1
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure 0/1 -- -- -- -- -- -- 0/1
Histiocytic disorders 1/2 -- -- -- -- -- -- 1/2
Inherited abnormalities of erythrocyte differentiation or function 0/2 1/1 -- -- -- -- -- 1/3
Inherited abnormalities of platelets 2/2 -- -- -- -- -- -- 2/2
Inherited disorders of metabolism 1/2 -- -- -- -- -- -- 1/2
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- 1/1 -- -- -- -- -- 1/1
Non-Hodgkin lymphoma -- 1/1 -- -- -- -- -- 1/1
Total 7/12 6/7 -- -- -- -- -- 13/19

Program Description:

Barnes-Jewish Hospital with St. Louis Children's Hospital is one of the nation's largest transplant centers. Siteman Cancer Center is Missouri's only NCI-designated Comprehensive Cancer Center. Our program is committed to providing the highest quality care and developing methods to further improve therapy outcomes.

Contact Information:

If you have transplant-related questions, please contact Marita Wehde, transplant center coordinator, at (314) 454-8378 or by e-mail at mwehde@dom.wustl.edu.

Program Type:

Adult and Pediatric

Attending Physicians:

(Medical Doctors)

Adult -

Camille Abboud, Jeffrey Bednarski, Amanda Cashen, John DiPersio, Todd Fehniger, Armin Ghobadi, Robert Hayashi, Meagan Jacoby, Lisa Madden, Iskra Pusic, Rizwan Romee, Mark Schroeder, Shalini Shenoy, Keith Stocker-Goldstein, Michael Tomasson, Geoffrey Uy, Ravi Vij, Matthew Walters, John Welch, Peter Westervelt

Transplants Performed:

Marrow/PBSC, single cord, and double cord

Cord blood transplants performed on:

Adult and pediatric

Find research trials at this center here:

ClinicalTrials.gov

Estimated Search & Transplant Costs

The costs for a transplant vary greatly from center to center and depend on factors such as health insurance, disease type and disease stage of the patient, as well as center-specific billing policies. Examples of costs in the search and transplant include:

  • The amount and geographic location of donors tested
  • Testing needed to confirm a match
  • Processing and collecting of tissue-typing samples
  • Donor workup testing needed
  • Getting the marrow, PBSC or cord blood unit for transplant

For the best understanding of costs of transplant and follow-up for a specific transplant center, contact the center's Financial Representative.

help Explain Transplant Costs at Different Centers

Resources for financial information

If you have questions about costs and financial services at this transplant center, you can contact the center's financial representative, Kim Gregory by e-mail at kgregory@dom.wustl.edu or by phone at (314) 747-8067.

Financial services at this center could include:

  • Health insurance information
  • Financial assistance
  • Patient-related resources

Additional Information

Further information about this center, including the number and type of transplants performed in each of the last three years, and the support groups offered, may be found in the BMT InfoNet Transplant Center Directory:
http://www.bmtinfonet.org/transplantcenters.

BMT InfoNet (Blood & Marrow Transplant Information Network) is a nonprofit organization that provides information and emotional support to transplant patients and their families.